Sarepta Therapeutics said Monday evening it will pause all shipments of Elevidys, its gene therapy for Duchenne muscular dystrophy, following a request by the Food and Drug Administration.
It’s a surprising reversal by Sarepta. The company had initially rejected the agency’s request, which was issued Friday.
Shipments will halt by close of business Tuesday evening, the company said.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
Source link
